Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal

- article written by vaccine's inventor, Dr. Brett Finlay -

BELLEVILLE, ON, Jan. 28 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that Econiche(TM), the world's first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157, has been cited in the February, 2010 issue of Scientific American (Vol. 302, No. 2).

The article, "The Art of Bacterial Warfare", was written by Dr. Brett Finlay, Peter Wall Distinguished Professor in the Michael Smith Laboratories, the biochemistry and molecular biology department, and the microbiology and immunology department at the University of British Columbia. Dr. Finlay's research led to the development of Econiche.

In his article, Dr. Finlay discusses the evolution of research into disease-causing bacteria and the discovery that bacteria have become increasingly adept at penetrating organs and tissues to survive and thrive in the human body. Dr. Finlay describes the E. coli O157 bacterium as having "perhaps the most remarkable method of locking itself onto a host cell", making its own receptor in the host's intestinal cells, anchoring it and allowing the bacterial toxins to enter the body and cause illness. Dr. Finlay further describes how E. coli O157 resides harmlessly in domestic cattle, but is released in their fecal matter where it can spread to human food and water supplies.

Most strains of E. coli are harmless but some, like O157, can cause severe illness and even be fatal when ingested by humans from contaminated meat, vegetables or water. Vaccination of cattle with Econiche can help reduce the risk of food and waterborne contamination with E. coli O157. The vaccine is fully licensed in Canada and is awaiting conditional licensing in the U.S.

An estimated 100,000 cases of human infection with the E. coli O157 organism are reported each year in North America. Two to seven per cent of those people develop haemolytic uremic syndrome (HUS), a disease characterized by kidney failure. Five percent of HUS patients die, many of them children and senior citizens, whose kidneys are more sensitive to damage.

About Scientific American

-------------------------

Scientific American, the oldest continuously published magazine in the U.S., has been bringing its readers unique insights about developments in science and technology for more than 160 years. More than 120 Nobel laureates have written for Scientific American, most of whom wrote about their prize-winning works years before being recognized by the Nobel Committee. In addition to the likes of Albert Einstein, Francis Crick, Jonas Salk and Linus Pauling, Scientific American continues to attract esteemed authors from many fields. Today, under the leadership of Editor in Chief Mariette DiChristina - who, in 2009, became the eighth editor in Scientific American's history and the first woman to hold the position - the magazine continues to be the world's premier source for advances in science and technology and how they shape our world. Scientific American is a truly global enterprise. The magazine publishes 15 foreign language editions and has a total of more than 1,000,000 copies in circulation worldwide. It has been accessible on the internet since March, 1996 at www.ScientificAmerican.com.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

%SEDAR: 00013159EF

SOURCE Telesta Therapeutics Inc.

For further information: For further information: Jennifer Shea, Vice-President, Communications, Investor & Government Relations, Bioniche Life Sciences Inc., Telephone: (613) 966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890